---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-24-000014"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:05:49.858538+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q4/FY2023: revenue down 40% to $78.5M; CFO resigns, vepdegestrant Fast Track

## Summary
- FY2023 revenue $78.5M vs $131.4M prior; Q4 revenue negative $43.1M. R&D expense $379.7M. Cash $1.27B, sufficient into 2027.
- Vepdegestrant: FDA Fast Track; Phase 1b combo with palbociclib CBR 63%, ORR 42%, median PFS 11.1 months. Phase 3 VERITAC-2 enrollment on track for 2H 2024.
- AR program: ARV-766 selected as lead; new Phase 1/2 data showed broader efficacy vs bavdegalutamide. Phase 2 PFS data mid-2024; regulatory discussions for Phase 3 in mCRPC Q2 2024.
- CFO Sean Cassidy resigns effective Feb 29; interim CFO Randy Teel. Board launched permanent replacement search.
- Closed $350M oversubscribed private placement; new Pfizer collaboration for E3 ligases. Regulatory clearance for ARV-102 (LRRK2) and ARV-393 (BCL6) Phase 1 trials.

## SEC filing metadata
- accession: 0001655759-24-000014
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/0001655759-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/arvn-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-24-000014
- JSON: https://secwatch.observer/filing/0001655759-24-000014.json
- Plain text: https://secwatch.observer/filing/0001655759-24-000014.txt

## Key facts
- Earnings Releases
  ARVINAS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575924000014/0001655759-24-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.